<?xml version="1.0" encoding="UTF-8"?>
<ref id="B117-biomedicines-08-00060">
 <label>117.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Andtbacka</surname>
    <given-names>R.H.I.</given-names>
   </name>
   <name>
    <surname>Ross</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Puzanov</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Milhem</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Collichio</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Delman</surname>
    <given-names>K.A.</given-names>
   </name>
   <name>
    <surname>Amatruda</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Zager</surname>
    <given-names>J.S.</given-names>
   </name>
   <name>
    <surname>Cranmer</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Hsueh</surname>
    <given-names>E.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial</article-title>
  <source>Ann. Surg Oncol.</source>
  <year>2016</year>
  <volume>23</volume>
  <fpage>4169</fpage>
  <lpage>4177</lpage>
  <pub-id pub-id-type="doi">10.1245/s10434-016-5286-0</pub-id>
  <pub-id pub-id-type="pmid">27342831</pub-id>
 </element-citation>
</ref>
